Garg Pankaj, Malhotra Jyoti, Kulkarni Prakash, Horne David, Salgia Ravi, Singhal Sharad S
Department of Chemistry, GLA University, Mathura 281406, India.
Departments of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center, National Medical Center, Duarte, CA 91010, USA.
Cancers (Basel). 2024 Jul 7;16(13):2478. doi: 10.3390/cancers16132478.
The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, necessitating the exploration of innovative therapeutic strategies. This review investigates the latest advancements in overcoming drug resistance mechanisms employed by cancer cells, focusing on emerging therapeutic modalities. The intricate molecular insights into drug resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, the promising avenues offered by targeted therapies, combination treatments, immunotherapies, and precision medicine approaches are highlighted. Specifically, the synergistic effects of combining traditional cytotoxic agents with molecularly targeted inhibitors to circumvent resistance pathways are examined. Additionally, the evolving landscape of immunotherapeutic interventions, including immune checkpoint inhibitors and adoptive cell therapies, is explored in terms of bolstering anti-tumor immune responses and overcoming immune evasion mechanisms. Moreover, the significance of biomarker-driven strategies for predicting and monitoring treatment responses is underscored, thereby optimizing therapeutic outcomes. For insights into the future direction of cancer treatment paradigms, the current review focused on prevailing drug resistance challenges and improving patient outcomes, through an integrative analysis of these emerging therapeutic strategies.
癌细胞耐药性的增加给现代肿瘤学带来了巨大挑战,因此需要探索创新的治疗策略。本综述研究了克服癌细胞耐药机制的最新进展,重点关注新兴的治疗方式。讨论了对耐药性的复杂分子见解,包括基因突变、外排泵、信号通路改变和微环境影响。此外,还强调了靶向治疗、联合治疗、免疫治疗和精准医学方法所提供的有前景的途径。具体而言,研究了将传统细胞毒性药物与分子靶向抑制剂联合使用以规避耐药途径的协同效应。此外,还探讨了免疫治疗干预的不断发展态势,包括免疫检查点抑制剂和过继性细胞疗法,以增强抗肿瘤免疫反应并克服免疫逃逸机制。此外,强调了生物标志物驱动策略在预测和监测治疗反应方面的重要性,从而优化治疗效果。为了深入了解癌症治疗模式的未来方向,本综述通过对这些新兴治疗策略的综合分析,聚焦于当前的耐药挑战和改善患者预后。